<DOC>
	<DOCNO>NCT03089138</DOCNO>
	<brief_summary>Efficacy Safety Regan Tangjiang treat common cold wind-heat syndrome : A Multicenter , Randomized , Double-Blind , Parallel-Group , Placebo Active-Controlled Phase 2b Study</brief_summary>
	<brief_title>Efficacy Safety Regan Tangjiang Treating Common Cold With Wind-heat Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Common Cold</mesh_term>
	<criteria>Diagnosis common cold accord Western Medicine，with symptom onset fever less 24 hour prior randomization； After onset disease , follow symptom : sore throat axillary temperature 38.5 38.9°C inclusive . Diagnosis windheat syndrome accord TCM； Aged 18 65 years； Willingness participate sign informed consent form . Participants Pneumonia , suppurative tonsillitis , acute tracheobronchitis , acute chronic sinusitis , pulmonary tuberculosis disease ; White blood cell count &gt; 11.0×109/L , neutrophil percentage &gt; 75 % ; Participants liver function 1.5 time higher normal upper limit serum creatinine high normal upper limit ; Participants severe primary disease cardiovascular , brain , lung , liver , kidney hematopoietic system , viral hepatitis , hemophilia , diabetes , psychosis ; Participants use drug treat common cold onset disease , include antiviral , antibiotic traditional Chinese medicine . Women pregnant breastfeeding ; Allergic condition ( refer history allergy two drug food ) allergy drug composition ( ) ; Participation another clinical study investigational drug within 3 month Participants suitable trial decide researcher reason , pregnancy , frequently change work living environment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>